Deciphera Pharmaceuticals (DCPH) Azione Prezzo
Deciphera Pharmaceuticals Prezzo
Negli ultimi 4 anni Deciphera Pharmaceuticals ha aumentato il fatturato del 59,9% all'anno, raggiungendo 163,36 Mio. USD. Per Deciphera Pharmaceuticals, il margine netto del -119,3% risulta in aumento rispetto al -766,0% di alcuni anni fa.
Deciphera Pharmaceuticals Prezzo delle azioni
Accedi a questi dati tramite l’API Eulerpool
100.000 richieste/mese gratis · nessuna carta di credito
Deciphera Pharmaceuticals Azione e analisi azionaria
Domande frequenti sull'azione Deciphera Pharmaceuticals
The business model of Deciphera Pharmaceuticals Inc revolves around developing and commercializing targeted therapeutics for the treatment of cancer. With a primary focus on kinase inhibitors, Deciphera Pharmaceuticals aims to address unmet medical needs and improve patient outcomes. The company prioritizes the discovery and development of small molecule drugs, leveraging its proprietary Kinase Switch Control Inhibitor Platform. By combining innovative science, strategic partnerships, and rigorous clinical research, Deciphera Pharmaceuticals aims to bring transformational therapies to patients living with cancer.
Deciphera Pharmaceuticals Inc is primarily active in the pharmaceutical industry.
Deciphera Pharmaceuticals Inc faces competition from several players in the market. Some of its main competitors include Blueprint Medicines Corporation, Array BioPharma Inc, and Loxo Oncology Inc. These companies are also engaged in the research and development of innovative therapies and treatments in the pharmaceutical industry. However, Deciphera Pharmaceuticals distinguishes itself through its unique approach and expertise in developing highly targeted precision medicine solutions. With its strong pipeline and advancements in kinase inhibitor drugs, Deciphera Pharmaceuticals Inc aims to stand out as a leading player in the market.
Deciphera Pharmaceuticals Inc. is a renowned biopharmaceutical company, known for its innovative approach in developing kinase inhibitor therapies to improve the lives of patients. Founded in 2003 and headquartered in Waltham, Massachusetts, Deciphera has made significant advancements in precision medicine by targeting the underlying causes of cancer and other diseases. With a focus on kinase switch control inhibitors (KSCIs), the company strives to provide effective treatment options for patients with various types of cancers and other serious diseases. Deciphera's dedication to research and development has led to the discovery of multiple potential drug candidates, establishing them as a key player in the pharmaceutical industry.
Deciphera Pharmaceuticals Inc has achieved several significant milestones. The company successfully developed and gained regulatory approval for their lead kinase inhibitor, Qinlock® (ripretinib), to treat advanced gastrointestinal stromal tumors (GIST). Deciphera Pharmaceuticals also obtained accelerated approval from the U.S. FDA for Qinlock® as a fourth-line therapy for GIST patients. Furthermore, they received breakthrough therapy designation from the FDA for Qinlock® in the second-line GIST treatment setting. These milestones highlight Deciphera Pharmaceuticals' commitment to developing innovative treatments for rare cancers and their dedication to advancing patient care.
Deciphera Pharmaceuticals Inc is primarily present in the United States.
Deciphera Pharmaceuticals Inc represents a strong commitment to improving patients' lives through innovative oncology treatments. Guided by a patient-centric approach, the company focuses on personalized medicine that targets specific cancer signaling pathways. Deciphera Pharmaceuticals Inc believes in advancing precision oncology therapies to address unmet medical needs and strives to make a significant impact in the field of cancer research. With their dedicated team and cutting-edge research, Deciphera Pharmaceuticals Inc is devoted to developing transformative therapies that provide hope and enhance the quality of life for patients with cancer.
16 analisti valutano attualmente l’azione Deciphera Pharmaceuticals: 7 raccomandano l’acquisto, 9 la tenuta e 0 la vendita. Per il 2026 gli analisti si aspettano per Deciphera Pharmaceuticals ricavi pari a 379,79 Mio. USD e un utile per azione di -0,58 USD.
Convertita al tasso di cambio attuale, l’azione Deciphera Pharmaceuticals quota 22,92 EUR (25,59 USD).
L’azione Deciphera Pharmaceuticals (DCPH) è quotata su 4 borse, tra cui: NASDAQ (DCPH), Frankfurt (D05.F), München (D05.MU), Düsseldorf (D05.DU).
Deciphera Pharmaceuticals Inc. is a biopharmaceutical company that develops innovative drugs for the treatment of cancer. The company operates in three main areas: clinical development, research and development, and marketing. The clinical development division focuses on developing drugs for the treatment of cancer. The research and development division specializes in discovering new drugs for cancer treatment. The marketing division works closely with partners to market the company's medical innovations worldwide. The company's goal is to improve the lives of cancer patients and extend their survival through the development and marketing of effective drugs. Overall, Deciphera Pharmaceuticals is committed to improving the lives of cancer patients globally.
Il attesa fatturato di Deciphera Pharmaceuticals ammonta a 379,79 Mio. USD. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.
Il attesa profitto di Deciphera Pharmaceuticals ammonta a -49,19 Mio. USD. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.
Il rapporto prezzo/utili (P/E) di Deciphera Pharmaceuticals è attualmente -44,22. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione Deciphera Pharmaceuticals.
Il rapporto prezzo/fatturato (P/S) di Deciphera Pharmaceuticals è attualmente 5,73. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione Deciphera Pharmaceuticals.
Il Quality Score AlleAktien per Deciphera Pharmaceuticals è 4/10.
L'ISIN di Deciphera Pharmaceuticals è US24344T1016. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.
Il WKN di Deciphera Pharmaceuticals è A2H48H. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.
Il ticker di Deciphera Pharmaceuticals è DCPH. Con questo simbolo di borsa vengono negoziate le azioni Deciphera Pharmaceuticals in borsa.
Azione Deciphera Pharmaceuticals
Gruppo di pari di Deciphera Pharmaceuticals
Deciphera Pharmaceuticals Ticker
Deciphera Pharmaceuticals FIGI
Altre metriche e analisi di Deciphera Pharmaceuticals in Deep Dive.
La nostra analisi azionaria dell'azione Deciphera Pharmaceuticals include importanti indicatori finanziari come il fatturato, l'utile, il P/E, il P/S, l'EBIT, oltre a informazioni sul dividendo. Inoltre, esaminiamo aspetti come le azioni, la capitalizzazione di mercato, il debito, il patrimonio netto e le passività di Deciphera Pharmaceuticals. Se state cercando informazioni più dettagliate su questi temi, sulle nostre sottopagine offriamo analisi approfondite: